Anke Hüls, Youran Tan, Emma Casey, Zhenjiang Li, Marla Gearing, Allan I. Levey, James J. Lah, Aliza P. Wingo, Dean P. Jones, Douglas I. Walker, Thomas S. Wingo, Donghai Liang
{"title":"阿尔茨海默病的代谢失调：脑代谢组学方法。","authors":"Anke Hüls, Youran Tan, Emma Casey, Zhenjiang Li, Marla Gearing, Allan I. Levey, James J. Lah, Aliza P. Wingo, Dean P. Jones, Douglas I. Walker, Thomas S. Wingo, Donghai Liang","doi":"10.1002/alz.70528","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>This study aimed to identify specific biological pathways and molecules involved in Alzheimer's disease (AD) neuropathology.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We conducted cutting-edge high-resolution metabolomics profiling of 162 human frontal cortex samples from the Emory Alzheimer's Disease Research Center (ADRC) brain bank with comprehensive neuropathological evaluations.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>We identified 155 unique metabolic features and 36 pathways associated with three well-established AD neuropathology markers. Of these, 18 novel metabolites were confirmed with level 1 evidence, implicating their involvement in amino acid metabolism, lipid metabolism, carbohydrate metabolism, nucleotide metabolism, and metabolism of cofactors and vitamins in AD neuropathology. Genetic variability influenced these associations, with non-carriers of the apolipoprotein E (<i>APOE</i>) ε4 allele showing stronger perturbations in metabolites including glucose and adenosine 5′-diphosphoribose.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>This study demonstrates the potential of high-resolution metabolomic profiling in brain tissues to elucidate molecular mechanisms underlying AD pathology. Our findings provide critical insights into metabolic dysregulation in AD and its interplay with genetic factors.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>This is one of the largest untargeted metabolomics studies of human brain tissue.</li>\n \n <li>155 metabolic features, and 36 metabolic pathways were linked to Alzheimer's disease (AD) neuropathology.</li>\n \n <li>Of these, 18 unique metabolites were confirmed with level 1 evidence.</li>\n \n <li>Glucose and adenosine 5′-diphosphoribose identified as key metabolic alterations in AD.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70528","citationCount":"0","resultStr":"{\"title\":\"Metabolic dysregulation in Alzheimer's disease: A brain metabolomics approach\",\"authors\":\"Anke Hüls, Youran Tan, Emma Casey, Zhenjiang Li, Marla Gearing, Allan I. Levey, James J. Lah, Aliza P. Wingo, Dean P. Jones, Douglas I. Walker, Thomas S. Wingo, Donghai Liang\",\"doi\":\"10.1002/alz.70528\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>This study aimed to identify specific biological pathways and molecules involved in Alzheimer's disease (AD) neuropathology.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>We conducted cutting-edge high-resolution metabolomics profiling of 162 human frontal cortex samples from the Emory Alzheimer's Disease Research Center (ADRC) brain bank with comprehensive neuropathological evaluations.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>We identified 155 unique metabolic features and 36 pathways associated with three well-established AD neuropathology markers. Of these, 18 novel metabolites were confirmed with level 1 evidence, implicating their involvement in amino acid metabolism, lipid metabolism, carbohydrate metabolism, nucleotide metabolism, and metabolism of cofactors and vitamins in AD neuropathology. Genetic variability influenced these associations, with non-carriers of the apolipoprotein E (<i>APOE</i>) ε4 allele showing stronger perturbations in metabolites including glucose and adenosine 5′-diphosphoribose.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>This study demonstrates the potential of high-resolution metabolomic profiling in brain tissues to elucidate molecular mechanisms underlying AD pathology. Our findings provide critical insights into metabolic dysregulation in AD and its interplay with genetic factors.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>This is one of the largest untargeted metabolomics studies of human brain tissue.</li>\\n \\n <li>155 metabolic features, and 36 metabolic pathways were linked to Alzheimer's disease (AD) neuropathology.</li>\\n \\n <li>Of these, 18 unique metabolites were confirmed with level 1 evidence.</li>\\n \\n <li>Glucose and adenosine 5′-diphosphoribose identified as key metabolic alterations in AD.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 9\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70528\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70528\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70528","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Metabolic dysregulation in Alzheimer's disease: A brain metabolomics approach
INTRODUCTION
This study aimed to identify specific biological pathways and molecules involved in Alzheimer's disease (AD) neuropathology.
METHODS
We conducted cutting-edge high-resolution metabolomics profiling of 162 human frontal cortex samples from the Emory Alzheimer's Disease Research Center (ADRC) brain bank with comprehensive neuropathological evaluations.
RESULTS
We identified 155 unique metabolic features and 36 pathways associated with three well-established AD neuropathology markers. Of these, 18 novel metabolites were confirmed with level 1 evidence, implicating their involvement in amino acid metabolism, lipid metabolism, carbohydrate metabolism, nucleotide metabolism, and metabolism of cofactors and vitamins in AD neuropathology. Genetic variability influenced these associations, with non-carriers of the apolipoprotein E (APOE) ε4 allele showing stronger perturbations in metabolites including glucose and adenosine 5′-diphosphoribose.
DISCUSSION
This study demonstrates the potential of high-resolution metabolomic profiling in brain tissues to elucidate molecular mechanisms underlying AD pathology. Our findings provide critical insights into metabolic dysregulation in AD and its interplay with genetic factors.
Highlights
This is one of the largest untargeted metabolomics studies of human brain tissue.
155 metabolic features, and 36 metabolic pathways were linked to Alzheimer's disease (AD) neuropathology.
Of these, 18 unique metabolites were confirmed with level 1 evidence.
Glucose and adenosine 5′-diphosphoribose identified as key metabolic alterations in AD.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
